Calebin A Inhibits Adipogenesis and Inflammation

Solution Overview

Problem

Current obesity management strategies lack effective, safe, and natural approaches to inhibit adipogenesis and modulate biochemical markers associated with obesity, such as leptin production, adiponectin expression, and inflammation caused by pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β.

Innovation Solution

Calebin A is used to inhibit adipogenesis, reduce leptin production, increase adiponectin expression, and suppress inflammation by pro-inflammatory cytokines, thereby preventing fat accumulation and managing obesity through its biomodulatory properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional obesity management strategies are used, then weight loss may be achieved, but safety and natural approach are compromised

Engineering Contradiction:

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs a natural compound (Calebin A) extracted from plant sources as a temporary, renewable therapeutic agent that can be administered and metabolized without long-term accumulation, replacing persistent synthetic drugs with a biodegradable natural alternative that maintains efficacy while improving safety profile

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the chemical parameter from synthetic pharmaceutical compounds to natural plant-derived compounds (Calebin A), fundamentally altering the source and composition parameter to achieve both therapeutic effect and enhanced safety with fewer side effects

Inventive Principle:

Principle #35Parameter changes

2Productivity

If adipogenesis is not inhibited, then fat cell development proceeds naturally, but obesity and related diseases increase

Engineering Contradiction:

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies Calebin A during the terminal differentiation stage of adipogenesis, intervening at a critical early point in fat cell development to prevent excessive adipocyte formation before it leads to obesity and related pathologies, thereby addressing the root cause rather than treating symptoms

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses Calebin A as a mediating substance that interferes with the adipogenesis process by modulating key molecular markers (leptin, adiponectin, TNF-α), acting as an intermediary agent that regulates fat cell development without directly causing the desired effect, thus enabling controlled inhibition of adipogenesis

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If leptin production is not inhibited, then normal adipocyte function is maintained, but obesity progression is accelerated

Engineering Contradiction:

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the production level parameter of leptin by administering Calebin A, which modulates the expression and secretion of leptin from adipocytes, thereby altering this key hormonal parameter to slow obesity progression while maintaining other essential adipocyte functions

Inventive Principle:

Principle #35Parameter changes

4Productivity

If adiponectin expression is not increased, then metabolic regulation is insufficient, but anti-obesity efficacy is reduced

Engineering Contradiction:

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent employs Calebin A as an intermediary substance that stimulates adiponectin expression and secretion, using this natural compound as a mediator to upregulate adiponectin levels and thereby improve metabolic regulation and insulin sensitivity in obese conditions

Inventive Principle:

Principle #24Intermediary (Mediator)

5Productivity

If inflammation caused by pro-inflammatory cytokines is not inhibited, then immune response is maintained, but obesity-related inflammation persists

Engineering Contradiction:

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) into a beneficial outcome by using Calebin A to selectively inhibit their excessive production in obese conditions, thereby transforming the inflammatory response from a harmful persistent state to a controlled, beneficial immune regulation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentEP2663185B1Calebin a for use in the treatment of inflammation and obesity

Publication Date: 2017.02.01

AI summary

The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-alpha), Interleukin-6 (IL-6) and Interleukin-1 (IL-1beta).